Patient
SITE005-0150
completed Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE005 (FRA) (Dr. Muller)
consented 2026-02-25
Adverse events
6
Serious AEs
1
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 6
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-11-09 (study day 64); relationship: not assessed
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-11-04 (study day 59); relationship: not assessed
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-10-13 (study day 37); relationship: NOT RELATED
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-09-25 (study day 19); relationship: not assessed
Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-09-17 (study day 11); relationship: NOT RELATED; serious criteria: hospitalization
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-09-13 (study day 7); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.